<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862195</url>
  </required_header>
  <id_info>
    <org_study_id>PROT001</org_study_id>
    <nct_id>NCT04862195</nct_id>
  </id_info>
  <brief_title>Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment</brief_title>
  <official_title>Double-blinded, Randomized, Adaptive Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices (Attune™ and Cerena™) as Interventions for Physical and Emotional Health in Adjunctive Oncology Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blue Note Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blue Note Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-significant risk, double-blinded, randomized, registrational study to compare&#xD;
      the effectiveness of two digital, software only, medical devices (SaMD) (attune™ and cerena™)&#xD;
      in reducing cancer-related anxiety and depression symptoms when used adjunctively with&#xD;
      multidisciplinary (medical, psychosocial) oncology usual care regimens for up to 10 weeks.&#xD;
&#xD;
      Study population will consist of up to 553 participants with stage I-III breast cancer or&#xD;
      stage I-III NSCLC. The primary endpoint is percent improvement in anxiety symptoms at Week 10&#xD;
      and secondary endpoints of percent improvement in depressive symptoms will be assessed at&#xD;
      Week 12.&#xD;
&#xD;
      An interim analysis for efficacy and futility will be conducted once 236 participants have&#xD;
      completed the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cancer-related symptoms of anxiety (1)</measure>
    <time_frame>Baseline up to Week 10</time_frame>
    <description>Percent reduction in PROMIS-A scores, reduction indicates reduced anxiety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer-related symptoms of depression (1)</measure>
    <time_frame>Baseline up to Week 10</time_frame>
    <description>Percent reduction in PROMIS-D scores, reduction indicates reduced depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-related symptoms of anxiety (2)</measure>
    <time_frame>Baseline up to Week 12</time_frame>
    <description>Percent reduction in PROMIS-A scores, reduction indicates reduced anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-related symptoms of anxiety (3)</measure>
    <time_frame>Baseline up to Week 10</time_frame>
    <description>Percent reduction in Clinical Global Impression Scale and Improvement scores, reduction indicates reduced anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-related symptoms of depression (4)</measure>
    <time_frame>Baseline up to Week 12</time_frame>
    <description>Percent reduction in Clinical Global Impression Scale and Improvement scores, reduction indicates reduced depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean mHealth App Usability Questionnaire (MAUQ) for Standalone mHealth Apps Used by Patients</measure>
    <time_frame>Baseline up to Week 10</time_frame>
    <description>Higher scores indicate higher ease of use / easier to use applications</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life via PROMIS-Global Health v1.2</measure>
    <time_frame>Weeks 10 and Week 12</time_frame>
    <description>The PROMIS Global Health measures assess an individual's physical, mental, and social health. The measures are generic, rather than disease-specific, and often use an &quot;In General&quot; item context as it is intended to globally reflect individuals' assessment of their health. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health (Promis-Global Health Scoring Manual, 2017). Higher scores for responses always indicate better health.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient self-efficacy via the Patient Activation Measure-13 (PAM-13)</measure>
    <time_frame>Weeks 10</time_frame>
    <description>Patient Activation Measures-the knowledge, skills, and confidence to manage one's health is associated with improved self-management behaviors in cancer patients. A patient activation measure (PAM) using PAM-13 will be used to assess participant engagement at baseline after PROMIS-A and PROMIS-D are completed and at Week 10. Higher scores indicate higher self-efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient self-efficacy via the Measurement of Current Status (MOCS) Part A and Part B</measure>
    <time_frame>Baseline, Week 6, and Week 10</time_frame>
    <description>The Measure of Current Status (MOCS) scale comes from research on the effects of a multi-modal cognitive-behavioral stress management intervention on the psychosocial well-being of cancer patients. The MOCS has two sections. Part A is items measuring participants' current self-perceived status on several skills that are targeted by the intervention: the ability to relax at will, recognize stress-inducing situations, restructure maladaptive thoughts, be assertive about needs, and choose appropriate coping responses as needed. Part B assesses potential &quot;nonspecific effects&quot; of the intervention: feelings of normalcy vs. alienation, sense of cohesiveness with other patients, perceptions of care from persons around them, and a sense of being better off than other cancer patients. All items were framed in such a way that they are sensible to participants in both conditions. MOCS measurements will be taken at Baseline, Week 6, and Week 10. Higher scores indicate higher self-efficacy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immune cell transcription</measure>
    <time_frame>Baseline up to Week 12</time_frame>
    <description>Analyses will focus on inflammatory gene expression and related gene regulation pathways due to their established relevance for disease progression/recurrence in the aftermath of cancer diagnosis and treatment, and their role in promoting symptoms of depression or anxiety via effects on central nervous system function</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">553</enrollment>
  <condition>Anatomic Stage I Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage II Breast Cancer AJCC v8</condition>
  <condition>Anatomic Stage III Breast Cancer AJCC v8</condition>
  <condition>Stage I Lung Cancer AJCC v8</condition>
  <condition>Stage II Lung Cancer AJCC v8</condition>
  <condition>Stage III Lung Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Attune™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Attune™ is a completely digital, 10-session, cognitive behavioral therapeutic intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cerena™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cerena™ is a completely digital, 10-session, health education and wellness intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Attune™</intervention_name>
    <description>Software as a medical device</description>
    <arm_group_label>Attune™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cerena™</intervention_name>
    <description>Software as a medical device</description>
    <arm_group_label>Cerena™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage I-III breast cancer or Stage I-III NSCLC who are currently in active treatment&#xD;
             or have completed initial cancer directed treatments (surgery, radiation,&#xD;
             chemotherapy) within the past 3 months;&#xD;
&#xD;
          -  Are experiencing at least moderate anxiety (GAD-7 &gt;10) or mild-to-moderate depression&#xD;
             (PHQ-8 score 5-11);&#xD;
&#xD;
          -  Are fluent in English; and&#xD;
&#xD;
          -  Have access to smartphone, or tablet capable of running iOS or Android software.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of cancer;&#xD;
&#xD;
          -  &lt;2-yr survival prognosis as determined by treating clinician;&#xD;
&#xD;
          -  Currently participating in investigative CBT trial for treatment of anxiety or&#xD;
             depression;&#xD;
&#xD;
          -  Participant is unable to complete training, has cognitive deficits, more severe&#xD;
             psychiatric conditions, lack of access to internet accessible device or psycho-social&#xD;
             conditions (e.g., other social conditions, that would interfere with adherence to&#xD;
             self-directed care), such that in investigator's opinion the participant would be&#xD;
             unable to complete the study;&#xD;
&#xD;
          -  Recently completed use of Blue Note Therapeutics Covid Cancer Care Program or other&#xD;
             Blue Note Therapeutics-sponsored study; and&#xD;
&#xD;
          -  PHQ-9 Q9 response &gt;0 AND Columbia Suicide Severity Risk Scale (or equivalent) score of&#xD;
             Category 2- &quot;suicidal ideation&quot; at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia A Ganz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raju Joshi, PhD</last_name>
    <phone>(424) 332-3551</phone>
    <email>rajuj@bluenotetx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
      <phone>562-693-4477</phone>
      <email>kbettino@airesearch.us</email>
    </contact>
    <contact_backup>
      <phone>562-652-6532</phone>
    </contact_backup>
    <investigator>
      <last_name>Christopher Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OPN Healthcare</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony P Lam, MD</last_name>
      <phone>818-507-4732</phone>
      <email>Dr.Anthony.Lam@OPNHC.com</email>
    </contact>
    <contact_backup>
      <last_name>Heather Lyon</last_name>
      <phone>(818) 507-4732</phone>
      <email>HeatherL@opnhc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony P Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Redlands Oncology</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92373</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Ramos</last_name>
      <phone>909-478-7973</phone>
      <email>PRamos@redlandshospital.org</email>
    </contact>
    <contact_backup>
      <last_name>Katherine Wall</last_name>
      <phone>909-478-7973</phone>
      <email>kwall@redlandshopsital.org</email>
    </contact_backup>
    <investigator>
      <last_name>Emad Ibrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Khoury, MD</last_name>
      <phone>562-693-4477</phone>
      <email>jkhoury@airesearch.us</email>
    </contact>
    <contact_backup>
      <last_name>Kristen Bettino</last_name>
      <phone>562-652-6532</phone>
      <email>kbettino@airesearch.us</email>
    </contact_backup>
    <investigator>
      <last_name>John Khoury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern CT Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Johnson</last_name>
      <phone>860-886-8362</phone>
      <email>sjohnson@echoct.com</email>
    </contact>
    <investigator>
      <last_name>Dinesh Kapur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinios Cancer Care</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615-7828</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Maddox</last_name>
      <phone>309-243-3607</phone>
      <email>mmaddox@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>SRINIVAS JUJJAVARAPU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rogel Cancer Center | University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0944</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lark Haunert</last_name>
      <phone>734-936-1283</phone>
      <email>lhaunert@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Lynn Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Jersey Center for Cancer Research</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Hamlin</last_name>
      <phone>732-840-8880</phone>
      <email>khamlin@njhoa.com</email>
    </contact>
    <investigator>
      <last_name>Apurv Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Strother, MD</last_name>
      <phone>541-768-4950</phone>
      <email>strotherchrq@samhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Anthony Franklin, RN</last_name>
      <phone>541-768-4351</phone>
      <email>anfranklin@samhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>John Strother, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compass Oncology</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Kern</last_name>
      <phone>360-597-1300</phone>
      <email>julian.kern@compassoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Blood and Cancer Care</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niyathi Nathwani, MD</last_name>
      <phone>803-329-7772</phone>
      <email>nanathwani@cbcca.net</email>
    </contact>
    <contact_backup>
      <last_name>Dhwani Mehta</last_name>
      <phone>(803) 286-9696</phone>
      <email>dmehta@cbcca.net</email>
    </contact_backup>
    <investigator>
      <last_name>Niyathi Nathwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorenzo Cohen, PhD</last_name>
      <phone>713-792-7734</phone>
      <email>lcohen@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Lorenzo Cohen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialty</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Thiel</last_name>
      <phone>253-428-8700</phone>
      <email>jthiel@southsoundcare.org</email>
    </contact>
    <investigator>
      <last_name>Frank Senecal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

